Public recall detail

ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections

medium
Recall Safety notice
Quick summary

Quick summary: ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Issue

Decreased overall survival and increased rate of serious adverse events have been observed in patients receiving ZYDELIG compared to the control groups in Phase 3 studies evaluating the addition of ZYDELIG to standard therapies for first line treatment of CLL and early lines of relapsed iNHL. The majority of events were infections, which included sepsis and pneumonia.

Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Official source Monitor products Back to recalls

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...